# Sermorelin FAQ: Approval History, Mechanism, Doses, and Safety, Cited

> Sermorelin FAQ: what it is, whether it works, why the branded product was discontinued, how it compares to tesamorelin and ipamorelin, side effects, and study timing — direct, cited answers.

The questions people actually ask about sermorelin — answered straight from the published record, with citations where the answer is a number.

## What is sermorelin used for?

Sermorelin was FDA-approved (as a prescription GHRH analog, NDA 020443) for evaluating and treating idiopathic growth hormone deficiency and short stature in children; it has also been studied in adult GH-axis research — aging, cognition, sleep, and body composition. It was withdrawn from the US market in 2008 for commercial reasons and is now compounded [1].

## Why was the branded sermorelin product discontinued?

The branded US sermorelin product (NDA 020443) was withdrawn from the market in 2008 for commercial reasons — not because of any safety or efficacy problem. Sermorelin remains available through compounding pharmacies and is treated as a Category 1 bulk drug substance under FDA's interim Section 503A policy. It was a market decision, not a safety action.

## Are there other peptides or applications being researched for GHRH analogs?

Beyond the GH/IGF-1 axis, GHRH-receptor agonist analogs have been explored preclinically for wound healing and cardiac repair [12], and a computational drug-repurposing screen flagged a sermorelin signal in glioma. These are hypothesis-generating preclinical and in-silico findings, not evidence that sermorelin treats those conditions.

## What is sermorelin?

Sermorelin (sermorelin acetate, GHRH(1-29)NH2 / GRF(1-29)) is a synthetic 29-amino-acid peptide matching the N-terminal 1-29 fragment of human growth hormone-releasing hormone — the shortest fragment that retains full activity at the GHRH receptor. It is a pituitary growth hormone secretagogue: it prompts the body to release its own growth hormone.

## What does sermorelin do to the body?

It binds GHRH receptors on anterior-pituitary somatotrophs, activating the cAMP/PKA pathway to stimulate synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1. Because it acts upstream on the pituitary rather than supplying external GH, somatostatin and IGF-1 feedback remain intact.

## Does sermorelin work?

In the FDA-approved pediatric indication, a multicenter trial showed once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. In older men, 14 days of subcutaneous GHRH(1-29) produced dose-related increases in 24-hour GH and IGF-1 [2]. Long-term adult anti-aging efficacy data remain limited [5].

## How long does it take for sermorelin to work?

Pharmacologically, a single dose elevates serum GH for roughly 3 hours despite the peptide's ~10-12 minute plasma half-life [3]. Endpoint changes were measured over longer windows in trials: 24-hour GH/IGF-1 over 14 days in older men [2], and first-year height velocity over a year in GH-deficient children [1].

## How does sermorelin compare to CJC-1295?

Both act at the GHRH receptor, but native GHRH(1-29) is rapidly cleared (~10-12 min half-life) [3]. Stabilizing modifications — the D-Ala2 substitution prolongs half-life and reduces metabolic clearance, and DAC (Drug Affinity Complex) albumin-binding technology underlies CJC-1295 with DAC — extend duration of action compared with native sermorelin.

## Sermorelin vs ipamorelin: what is the difference?

Sermorelin is a GHRH analog acting at the GHRH receptor on somatotrophs. Ipamorelin is a growth-hormone-releasing peptide (GHRP) that acts at the separate ghrelin/GHS receptor. Because they engage different receptors, the two classes are often studied or paired together.

## Does sermorelin actually help with sleep, or is it waking me up instead?

GHRH has documented sleep-promoting effects in research: it increased slow-wave sleep in normal men, and its sleep-endocrine effects depend on the time of administration. GH is secreted largely during slow-wave sleep, which is part of the rationale for bedtime dosing in studies [1].

## Why is it recommended to inject sermorelin at night?

Endogenous GH is released in pulses, with the largest surge during early slow-wave sleep. Trials commonly administered GHRH(1-29) at bedtime — the pediatric multicenter trial dosed subcutaneously at bedtime [1] — to align with the body's natural nocturnal GH pulse. This describes study protocols, not a self-administration schedule.

## Does sermorelin burn fat?

Direct sermorelin fat-loss trials are limited. The evidence comes largely from the related stabilized GHRH analog tesamorelin, which significantly reduced visceral adipose tissue versus placebo, and from GH's role in lipolysis [6]. This is GHRH-axis / drug-class evidence, not a sermorelin-specific cosmetic claim.

## Is sermorelin effective for weight loss?

There is no robust sermorelin weight-loss trial evidence. The body-composition signal is from tesamorelin's effect on visceral fat in specific clinical populations and from GH's role in lipolysis [6] — not a demonstrated general weight-loss effect of sermorelin. Anti-aging and weight marketing outpaces the evidence [5].

## Does sermorelin affect testosterone?

Sermorelin acts on the GH/IGF-1 axis, a separate hormonal pathway from the hypothalamic-pituitary-gonadal axis that governs testosterone. The men's-health literature frames GH secretagogues around raising IGF-1 and body composition [2] rather than directly altering testosterone.

## Will sermorelin raise my IGF-1 levels?

Yes — by stimulating GH release, sermorelin drives hepatic IGF-1 production. In older men, 14 days of subcutaneous GHRH(1-29) produced dose-related IGF-1 increases that, at the high dose, brought GH/IGF-1 levels in line with those of young men, all within the physiologic range [2].

## Does sermorelin build muscle?

There is no direct sermorelin muscle-hypertrophy trial in this literature. The mechanistic rationale is the GH/IGF-1 axis, and reviews discuss GH/IGF-1 modulation as a candidate strategy against age-related muscle loss (sarcopenia) [15] — a hypothesis-level framing, not demonstrated muscle-building in healthy adults.

## How does sermorelin differ from direct HGH injections?

Direct HGH supplies exogenous growth hormone, bypassing the pituitary and overriding feedback. Sermorelin acts upstream on the pituitary to prompt the body's own GH, so somatostatin and IGF-1 negative feedback remain intact — an argument editorial authors have made for it as a more physiologic approach to adult GH insufficiency [4].

## Does sermorelin affect the brain?

GHRH administration has measurable neuroendocrine effects: in a randomized trial in older adults (using the GHRH analog tesamorelin) it had a favorable effect on cognition [6], and a related study found GHRH altered brain GABA levels in mild cognitive impairment and healthy aging.

## Can sermorelin or GHRH improve cognition in older adults?

In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily subcutaneous GHRH analog had a favorable effect on cognition, raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%, with mild adverse events [6].

## What are the side effects of sermorelin?

Across studies, reported effects of GHRH(1-29) have generally been mild, often local injection-site reactions; trials such as the older-adult cognition study reported mild adverse events [6]. Long-term adult tolerability data are limited, and because GH/IGF-1 are mitogenic, chronically raising them is a recognized theoretical safety consideration [5].

## When is the best time to take sermorelin?

Studies most often administered GHRH(1-29) subcutaneously at bedtime to coincide with the body's natural nocturnal GH pulse during slow-wave sleep [1]. This describes study protocols, not a dosing recommendation for self-administration.

## Is 3 months of sermorelin enough?

Study durations varied with the endpoint: 14 days for 24-hour GH/IGF-1 changes in older men [2], 20 weeks for the older-adult cognition trial [6], and a full year (and up to 2 years) for height-velocity outcomes in children [1][8]. There is no established fixed course; durations were set by what each study measured.

---

A status-console reading of the sermorelin record — every regulatory and GH/IGF-1 fact tagged with its source and its operational state, the formerly-approved-now-compounded standing reported as filed and the thin adult anti-aging evidence flagged in plain view; no clinic behind this console and nothing here dosed, dispensed, or sold.